Cabozantinib (XL184) for the treatment of locally advanced or metastatic progressive medullary thyroid cancer.

@article{Viola2013CabozantinibF,
  title={Cabozantinib (XL184) for the treatment of locally advanced or metastatic progressive medullary thyroid cancer.},
  author={David Viola and Virginia Cappagli and Rossella Elisei},
  journal={Future oncology},
  year={2013},
  volume={9 8},
  pages={1083-92}
}
Cabozantinib (XL184) is an oral multiple receptor tyrosine kinase inhibitor manufactured by Exelixis Inc., CA, USA. It mainly inhibits three tyrosine kinase receptors: MET, VEGFR2 and RET. In both preclinical and clinical studies it has been shown to inhibit tumor angiogenesis, invasiveness and metastases. The most frequent side effects are fatigue, diarrhea, decreased appetite, nausea, weight loss and palmar-plantar erythrodysesthesia. A Phase III clinical trial (EXAM study) of XL184 versus… CONTINUE READING
20 Citations
60 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 20 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 60 references

clinicopathologic features and long­term follow­up of 65 patients treated during 1946 through 1970

  • H Gharib, WM McConahey, carcinoma Tiegs RD et al. Medullary thyroid
  • Mayo Clin. Proc. 67, 934–940
  • 1992
Highly Influential
7 Excerpts

An international double­blind, randomized, placebo­controlled Phase III (EXAM) of cabozantinib (XL184) in medullary thyroid cancer patients with documented RECIST progression at baseline

  • P Schoffski, R Elisei, S Müller
  • J. Clin. Oncol
  • 2012
Highly Influential
4 Excerpts

Clinical and biochemical activity in the EXAM trial, a Phase III study of cabozantinib (XL184) in patients with hereditary and non­hereditary medullary thyroid carcinoma

  • R Elisei, S Mueller, P Schoffski
  • (MTC). Eur. Thyroid J. 1, Abstract
  • 2012
Highly Influential
4 Excerpts

Activity of cabozantinib ( XL 184 ) in metastatic NSCLC : results from a Phase II randomized discontinuation trial ( RDT )

  • BA Hellerstedt, G Edelman, NJ Vogelzang
  • J . Clin . Oncol .
  • 2012
Highly Influential
1 Excerpt

Antitumor activity of cabozantinib ( XL 184 ) in a cohort of patients ( pts ) with differentiated thyroid cancer ( DTC )

  • ME Cabanillas, MS Brose, DA Ramies
  • J . Clin . Oncol .
  • 2012
Highly Influential
1 Excerpt

Similar Papers

Loading similar papers…